APPENDIX I

ACCOUNTANTS’ REPORT

Construction in progress as of December 31, 2016 primarily related to the BeiGene Suzhou
manufacturing and laboratory facility that was put
into service in the third quarter of 2017.
Construction in progress as of December 31, 2017 and March 31, 2018 of US$26,125,000 and
US$38,584,000 primarily related to the buildout of the Guangzhou manufacturing facility. In the year
ended December 31, 2017 and the three months ended March 31, 2018, assets totaling US$24,537,000
and US$662,000 related to the Suzhou facilities were transferred to laboratory equipment,
manufacturing equipment and leasehold improvements from construction in progress. Depreciation
expense for the years ended December 31, 2016 and 2017 and the three months ended March 31, 2017
and 2018 were US$1,909,000, US$4,340,000, US$864,000 and US$1,984,000, respectively.

11. MANUFACTURING FACILITY IN GUANGZHOU

On March 7, 2017, BeiGene HK, a wholly owned subsidiary of the Company, and Guangzhou
GET Technology Development Co., Ltd. (“GET”), entered into a definitive agreement to establish a
commercial scale biologics manufacturing facility in Guangzhou, Guangdong Province, PRC.

On March 7, 2017, BeiGene HK and GET entered into an Equity Joint Venture Contract (the “JV
Agreement”). Under the terms of the JV Agreement, BeiGene HK made an initial cash capital
contribution of RMB200,000,000 and a subsequent contribution of one or more biologics assets in
exchange for a 95% equity interest in BeiGene Biologics. GET made a cash capital contribution of
RMB100,000,000 to BeiGene Biologics, representing a 5% equity interest in BeiGene Biologics. In
addition, on March 7, 2017, BeiGene Biologics entered into a contract with GET, under which GET
agreed to provide a RMB900,000,000 loan (the “Shareholder Loan”) to BeiGene Biologics (see note
II.20). BeiGene Biologics is working to establish a biologics manufacturing facility in Guangzhou,
through a wholly-owned subsidiary, the BeiGene Guangzhou Factory, to manufacture biologics for the
Company and its subsidiaries.

On April 11, 2017, BeiGene HK, GET and BeiGene Biologics amended the JV Agreement and
the capital contribution agreement, among other things, to adjust the capital contribution schedules
and adjust the initial term of the governing bodies and a certain management position. On April 13,
2017 and May 4, 2017, BeiGene HK made cash capital contributions of RMB137,830,000 and
RMB2,415,000, respectively, into BeiGene Biologics. The remainder of the cash capital contribution
from BeiGene HK to BeiGene Biologics will be paid by April 10, 2020. On April 14, 2017, GET made
cash capital contributions of RMB100,000,000 into BeiGene Biologics. On April 14, 2017, BeiGene
Biologics drew down the Shareholder Loan of RMB900,000,000 from GET (as further described in
note II.20).

On October 24, 2017, BeiGene HK and BeiGene Biologics entered into an Equity Transfer
Agreement. Under the terms of the Equity Transfer Agreement, BeiGene HK agreed to transfer 100%
equity interest of BeiGene Shanghai
into BeiGene Biologics. The transfer consideration for the
purchased interests under this Equity Transfer Agreement is the fair value of the 100% equity of
BeiGene Shanghai appraised by a qualified Chinese valuation firm under the laws of the PRC. On
November 24, 2017,
the 100% equity interest of BeiGene Shanghai was transferred to BeiGene
Biologics. Upon the transfer of equity in BeiGene Shanghai, BeiGene HK fulfilled its contribution
obligation to subscribe for registered capital in BeiGene Biologics and BeiGene HK’s equity interest

— I-46 —

